Fig. 2.

VAS score (mm) by visit. a Pelvic pain (end-of-treatment group sizes: placebo n = 97, relugolix 10 mg n = 103, relugolix 20 mg n = 100, relugolix 40 mg n = 103, leuprorelin n = 80). b Dysmenorrhea (end-of-treatment group sizes: placebo n = 97, relugolix 10 mg n = 103, relugolix 20 mg n = 100, relugolix 40 mg n = 103, leuprorelin n = 80). c Dyspareunia (end-of-treatment group sizes: placebo n = 36, relugolix 10 mg n = 50, relugolix 20 mg n = 40, relugolix 40 mg n = 39, leuprorelin n = 23). Data are mean ± SD. SD standard deviation; VAS visual analog scale